- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03461302
Efficacy of Topical Coal Tar in Children With Atopic Dermatitis
A Randomized Controlled Pilot Study Comparing the Efficacy of Topical Coal Tar to Topical Corticosteroids in Children Aged 1 to < 16 Years With Moderate-severe Atopic Dermatitis
Rationale/hypothesis: Atopic dermatitis (AD) is an inflammatory skin disease, occurring most frequently in children. Currently, topically applied corticosteroids are used as a standard anti-inflammatory treatment. When a corticosteroid with a high potency is used for a long period of time, adverse effects like skin atrophy and systemic effects may occur, especially in children. In addition, corticophobia among patients is an issue that warrants alternatives for the treatment of AD in children. An alternative treatment is the topical application of coal tar, which is known to be an effective and safe treatment for AD for ages, and is used in our department for decennia. Although there is convincing evidence in the literature on the safety of coal tar, evidence in the literature on the efficacy of coal tar in the treatment of AD is lacking, especially in children.
Objective: To evaluate efficacy of topical treatment with coal tar compared to topical treatment with corticosteroids in children aged 1 to <16 years with moderate to severe AD
Study design: investigator-initiated, parallel-group randomized controlled pilot study
Study population: Children aged 1 to <16 years with moderate-severe AD
Intervention: Patients will be randomized in two groups: (1) topical treatment with coal tar or (2) topical treatment with moderate potency corticosteroids for a treatment duration of 4 weeks.
Main study parameters/endpoints: The primary outcome is the percentage change in EASI score at week 2.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Tessa Kouwenhoven, MD
- Phone Number: +31(0)243610265
- Email: Tessa.Kouwenhoven@radboudumc.nl
Study Locations
-
-
-
Nijmegen, Netherlands
- Recruiting
- Department of Dermatology
-
Contact:
- Tessa Kouwenhoven, MD
- Phone Number: +31(0)243610265
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of AD based on the criteria of Hanifin and Rajka
- Moderate to severe AD based on EASI score >7.1
- Willing and able to comply with visits and study-related procedures
- Provide signed informed consent (if patient >12 years of age) and/or signed informed consent provided by the parents or legal guardian (all participating patients)
- Able to understand and complete study-related questionnaires, or parent or legal guardian is able to understand and complete study-related questionnaires
- Willing to avoid excessive sunlight
Exclusion Criteria:
- Hypersensitivity and/or intolerance to topical corticosteroids or topical coal tar
Treatment with any of the following before baseline:
- Topical treatment with corticosteroids within 24 hours before baseline
- Topical treatment with coal tar, tacrolimus and/or pimecrolimus within 2 weeks before baseline
- Topical treatment with antibiotics or antifungal treatment within 7 days before baseline
- Systemic corticosteroids, immunosuppressive/immunomodulatory drugs or phototherapy for AD within 8 weeks before baseline
- Investigational drugs within 8 weeks or 5 half-lives (whichever is longer)
- Use of systemic antibiotic therapy, systemic antifungal therapy and/or biologicals within 6 months before baseline
Planned or anticipated use of any prohibited medication during the treatment and follow-up period:
- Other medication than the prescribed study medication used for the treatment of AD, including topical calcineurin inhibitors, prescription moisturizers containing additives such as urea, antihistamines, phototherapy, systemic treatment with an immunosuppressive/immunomodulatory agent such as cyclosporine, methotrexate or biologics
- Systemic antibiotic and/or antifungal therapy
- Indication for systemic therapy or a medical need to use a higher level of topical corticosteroids than moderate potency topical corticosteroids
- Pregnancy or breast feeding, or planning to become pregnant or breast feed
- Presence of skin co-morbidities that may interfere with study assessments
- Presence of concomitant illness that would, in the investigator's judgment, adversely affect the patient's participation in the study
- Presence of chronic hepatic or renal insufficiency
- Presence of immunodeficiency syndromes including HIV
- Presence of HBV or HCV
- Any other medical or psychological condition that would represent an unreasonable risk to the patient, make the patient's participation unreliable or interfere with study assessments
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Topical Coal Tar treatment
|
Solution carbonis detergens 10% in cremor vaselini lanette FNA and pix lihantracis 3% in zinc oxide paste
|
Active Comparator: Topical Corticosteroids treatment
|
Clobetasone butyrate 0.05% ointment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease activity
Time Frame: 4 weeks
|
Disease-activity measured by Eczema Area and Severity Index (EASI)
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pruritus
Time Frame: 4 weeks
|
VAS pruritus
|
4 weeks
|
Health-related quality of life
Time Frame: 4 weeks
|
DLQI
|
4 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL59682.091.16
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
ShaperonNot yet recruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of Scalp
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
PfizerRecruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Czechia, Canada, Poland
-
AmgenCompletedDermatitis, Atopic DermatitisCanada, United States, Japan
-
Hadassah Medical OrganizationUnknownATOPIC DERMATITIS
-
SanofiCompletedAtopic Dermatitis | Dermatitis AtopicChina
-
SanofiCompletedDermatitis AtopicSaudi Arabia, Kuwait, United Arab Emirates
-
National Institute of Allergy and Infectious Diseases...Atopic Dermatitis Research NetworkCompletedAtopic Dermatitis (AD) | Non-atopic Healthy ControlsUnited States
-
AbbVieRecruiting
Clinical Trials on Topical coal tar
-
Postgraduate Institute of Medical Education and...Unknown
-
University of California, San FranciscoNational Psoriasis FoundationRecruitingPsoriasis | Psoriasis VulgarisUnited States
-
ABAStroke Sp. z o.o.Recruiting
-
Laboratorios Silanes S.A. de C.V.CompletedSeborrheic Dermatitis | Psoriasis of ScalpMexico
-
Canopy Growth CorporationActive, not recruiting
-
Senscio SystemsCentral Maine Medical FamilyUnknown
-
Bjelovar General HospitalCompleted
-
University of British ColumbiaMinistry of Health, British ColumbiaCompletedQuality Improvement | Clinical AuditCanada
-
HDL TherapeuticsMedStar Heart and Vascular InstituteUnknownHomozygous Familial Hypercholesterolemia | HoFHUnited States
-
University of California, San DiegoCongressionally Directed Medical Research ProgramsEnrolling by invitationRotator Cuff Repair | Ankle Arthroplasty or Arthrodesis | Hallux Valgus (Bunion) ResectionUnited States